Kisspeptin

Kisspeptin is a naturally occurring neuropeptide that plays a pivotal role in regulating human reproduction and sexual behaviour. Acting upstream within the hypothalamic–pituitary–gonadal (HPG) axis, kisspeptin stimulates gonadotropin-releasing hormone (GnRH) secretion, leading to downstream release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). Unlike many investigational compounds in sexual and reproductive health, kisspeptin is supported by robust human clinical data. This paper reviews the physiological mechanisms of kisspeptin and evaluates current human research across sexual desire, fertility, and hormonal regulation. 

The discovery of kisspeptin has significantly advanced understanding of reproductive neuroendocrinology. Initially identified for its role in suppressing tumour metastasis, kisspeptin is now recognised as a master regulator of GnRH pulsatility. Disruption of kisspeptin signalling is associated with delayed puberty, infertility, and hypogonadotropic hypogonadism, underscoring its essential physiological function. 

Kisspeptin exerts its effects by binding to the KISS1 receptor (KISS1R) located in the hypothalamus. Activation of this receptor initiates GnRH release, restoring or enhancing physiological hormone pulsatility rather than overriding endogenous feedback systems. In addition to endocrine regulation, kisspeptin directly influences limbic brain regions involved in emotional processing, sexual motivation, and arousal, differentiating it from therapies that act solely via peripheral vascular or melanocortin pathways. 

Human randomised controlled trials demonstrate that kisspeptin enhances sexual brain processing in both men and women. Functional MRI studies report increased activation in the amygdala, hippocampus, and other desire-related brain regions following kisspeptin administration. In men with hypoactive sexual desire disorder (HSDD), kisspeptin has been associated with significantly increased erectile response to erotic stimuli and improvements in sexual wellbeing scores. In women with HSDD, kisspeptin restored attraction-related neural activity while reducing aversive responses, supporting its potential role in central desire modulation. 

Kisspeptin has been extensively studied in assisted reproductive technology, particularly in vitro fertilisation (IVF). Clinical trials demonstrate that kisspeptin can induce a physiological LH surge sufficient for oocyte maturation, resulting in successful pregnancies. Importantly, kisspeptin triggers are associated with a reduced risk of ovarian hyperstimulation syndrome compared with traditional human chorionic gonadotropin (hCG). In women with hypothalamic amenorrhea, kisspeptin has been shown to restore pulsatile LH secretion and support ovulatory function. 

By stimulating LH and FSH release, kisspeptin promotes endogenous testosterone production in men and estradiol production in women. This upstream mechanism preserves natural endocrine feedback loops, distinguishing kisspeptin from exogenous hormone replacement strategies and making it a compelling area of endocrine research. 

Kisspeptin represents one of the most clinically validated peptides in reproductive and sexual health research. Human studies support its role in restoring physiological hormone signalling, enhancing sexual desire, and improving fertility outcomes. Its central, brain-mediated mechanism positions kisspeptin as a unique and promising research target distinct from peripheral or suppressive therapies. 

Selected External Research Studies 

• https://www.nejm.org/doi/full/10.1056/NEJMoa1101739 

• https://pubmed.ncbi.nlm.nih.gov/30810820/ 

• https://pubmed.ncbi.nlm.nih.gov/29754866/ 

• https://academic.oup.com/jcem/article/99/11/E1934/2537396